Apollomics Appoints New CFO, Matthew Plunkett
Ticker: APLMW · Form: 6-K · Filed: Mar 4, 2024 · CIK: 1944885
| Field | Detail |
|---|---|
| Company | Apollomics Inc. (APLMW) |
| Form Type | 6-K |
| Filed Date | Mar 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: personnel-change, cfo-appointment
TL;DR
Apollomics names Matthew Plunkett as new CFO, effective immediately.
AI Summary
Apollomics Inc. announced on March 4, 2024, the appointment of Matthew Plunkett, Ph.D., as its new Chief Financial Officer (CFO), effective immediately. Dr. Plunkett brings over 25 years of experience in the biopharmaceutical sector, previously serving as CFO at Aeovian Pharmaceuticals.
Why It Matters
The appointment of a new CFO can signal strategic shifts or financial restructuring within a company, impacting investor confidence and future financial operations.
Risk Assessment
Risk Level: low — This filing is a routine personnel announcement and does not contain significant financial or operational risks.
Key Players & Entities
- Apollomics Inc. (company) — The company making the announcement.
- Matthew Plunkett, Ph.D. (person) — Newly appointed Chief Financial Officer.
- March 4, 2024 (date) — Date of the announcement.
- Aeovian Pharmaceuticals (company) — Previous employer of the new CFO.
FAQ
Who has been appointed as the new Chief Financial Officer of Apollomics Inc.?
Matthew Plunkett, Ph.D. has been appointed as the new Chief Financial Officer of Apollomics Inc.
When was the appointment of the new CFO effective?
The appointment of Matthew Plunkett, Ph.D. as CFO was effective immediately on March 4, 2024.
What is the relevant experience of the new CFO?
Dr. Plunkett brings over 25 years of diverse strategic and financial experience within the biopharmaceutical sector.
What was the previous role of the new CFO?
Matthew Plunkett, Ph.D. was most recently the Chief Financial Officer at Aeovian Pharmaceuticals.
What is the filing date of this Form 6-K?
This Form 6-K was filed on March 4, 2024.
Filing Stats: 410 words · 2 min read · ~1 pages · Grade level 11.5 · Accepted 2024-03-04 07:36:56
Filing Documents
- d769036d6k.htm (6-K) — 11KB
- d769036dex991.htm (EX-99.1) — 10KB
- g769036ddsp1.jpg (GRAPHIC) — 9KB
- 0001193125-24-056857.txt ( ) — 35KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. APOLLOMICS INC Date: March 4, 2024 By: /s/ Guo-Liang Yu Name: Guo-Liang Yu Title: Chief Executive Officer